文献速递呼吸衰竭与机械通气儿科与产科急症重症综合管理与镇静镇痛

基于细胞因子的策略改善儿童ARDS预后富集

Cytokine-based strategies to improve prognostic enrichment of pediatric ARDS.
PubMed 文献 · Crit Care · 2026-07-01
一句话结论在儿童ARDS中,含CCL7和IL-18的细胞因子模型较传统IL-6/TNFR1/碳酸氢盐模型改善90天死亡预后判别,但验证集AUC仅0.66。

本研究基于LEOPARDS前瞻性多中心队列(500例儿童ARDS),在ARDS后24小时内检测血浆细胞因子。传统3项(IL-6、TNFR1、碳酸氢盐)高/低炎症表型模型对90天死亡的判别力有限(AUC 0.62,灵敏度26%,PPV 24%)。CCL7(MCP-3)与90天死亡关联最显著(p<0.0001)。含CCL7和IL-18的两项及三项模型在训练集(n=300)AUROC 0.72-0.73、验证集(n=200)AUROC 0.66,净重分类改善约40%。免疫抑制状态独立与90天死亡相关(p<0.0001)。

要点

  • 传统3项(IL-6、TNFR1、碳酸氢盐)模型对儿童ARDS 90天死亡判别力有限:AUC 0.62,灵敏度26%,PPV 24%。
  • CCL7(MCP-3)是与90天死亡关联最显著的细胞因子(p<0.0001),优于其他额外检测的细胞因子。
  • 含CCL7+IL-18的两项模型和CCL7+IL-18+TNFR1的三项模型训练集AUROC 0.72-0.73,验证集AUROC 0.66。
  • 免疫抑制状态独立与90天死亡相关(p<0.0001),最佳预后模型可能因免疫抑制状态而异。
  • 上述细胞因子模型目前仅用于预后富集研究,尚不能作为床旁决策阈值。

适用人群与场景

  • LEOPARDS前瞻性多中心队列纳入的500例儿童ARDS患者,血浆样本在ARDS后24小时内获取。
  • 原文未明确列出排除标准。

诊断标准与关键阈值

  • 传统高/低炎症表型模型由IL-6、TNFR1和碳酸氢盐三项构成,原文未给出各项具体界值。
  • 含CCL7和IL-18的两项及三项模型原文未给出床旁可用的具体阈值。

处置流程与药物剂量

  • 原文未提及细胞因子检测结果指导的具体治疗或药物处置方案。

红旗征与不能漏的情况

  • 免疫抑制状态独立与90天死亡相关(p<0.0001),提示该类患儿预后更差。

研究设计与关键结果

  • 研究类型:前瞻性多中心队列研究(LEOPARDS,NCT04113434),样本量500例儿童ARDS。
  • 传统3项模型对90天死亡判别力有限:AUC 0.62,灵敏度26%,PPV 24%;队列中14%为高炎症表型,90天死亡率13.4%。
  • CCL7(MCP-3)与90天死亡关联最显著(p<0.0001)。
  • CCL7+IL-18两项模型和CCL7+IL-18+TNFR1三项模型:训练集(n=300)AUROC 0.72-0.73,验证集(n=200)AUROC 0.66,净重分类改善约40%。
  • 免疫抑制状态独立与90天死亡相关(p<0.0001),最佳预后模型可能因免疫抑制状态而异。

证据类型、等级与局限

  • 证据类型:前瞻性多中心队列研究(原文未给出证据等级或推荐强度)。
  • 局限:预后模型仅在训练集和验证集中表现中等判别力(验证集AUROC 0.66),原文未报告外部验证;细胞因子检测尚未转化为床旁可用的治疗决策工具。

对床旁实践的改变

  • 本研究提示传统IL-6/TNFR1/碳酸氢盐模型对儿童ARDS预后富集能力有限,不应单独用于床旁风险分层。
  • 含CCL7和IL-18的模型可能改善预后判别,但目前仅为研究工具,尚不能替代临床决策。
  • 对免疫抑制状态的儿童ARDS患儿应警惕更差预后(独立关联90天死亡)。
  • 原文未提供细胞因子检测指导免疫调节治疗的具体方案或适用人群。

指南或共识出处

  • 原文未提及指南或共识;研究注册号NCT04113434(LEOPARDS研究)。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Hyper-inflammation is common to multiple critical care syndromes, including acute respiratory distress syndrome (ARDS) and sepsis, and is associated with worse outcomes. A signature of hyper-inflammatory ARDS has been described in adults using IL-6, TNFR1, and bicarbonate, and has prognostic utility. We investigated the application of this traditional parsimonious signature to pediatric ARDS patients and tested whether we could improve prognostic enrichment using other cytokines.

METHODS: We leveraged a prospective multicenter cohort study of 500 children with ARDS (Linking Endotypes and Outcomes in Pediatric Acute Respiratory Distress Syndrome [LEOPARDS]; NCT04113434) study. Plasma samples were obtained within 24 h of ARDS. Cytokines were measured using microfluidic immunoassay (Ella™).

RESULTS: The traditional 3-term (IL-6, TNFR1, and bicarbonate) hyper-/hypo-inflammatory phenotype model demonstrated modest utility for 90-day mortality (AUC 0.62, sensitivity 26%, positive predictive value [PPV] 24%) in LEOPARDS (14% hyper-inflammatory, 13.4% 90-day mortality). Of the additional cytokine biomarkers tested, CCL7 (MCP-3) demonstrated the most significant association with 90-day mortality (p < 0.0001). Parsimonious two-term (CCL7, IL-18) and three-term models (CCL7, IL-18, TNFR1) demonstrated mortality discrimination in both training (n = 300) (AUROCs 0.72-0.73) and validation (n = 200) (AUROCs 0.66) sets, with improved net reclassification (~ 40% improved classification). Immune compromised status was independently associated with 90-day mortality (p < 0.0001) with evidence that the optimal prognostic model may vary by immunocompromised status.

CONCLUSIONS: Cytokine-based prognostic enrichment strategies show promise for children with ARDS. In addition to models based primarily on IL-6 and TNFR1, models including CCL7 and IL-18 may be of utility for assessing the full spectrum of inflammation. Future studies should focus on identifying whether cytokine-based enrichment can identify specific pathways to inform immunomodulatory interventions.

TRIAL REGISTRATION: Clinical Trial NCT04113434 was registered 2019-10-02.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Halstead ES, Umstead TM, Chroneos ZC, et al. Cytokine-based strategies to improve prognostic enrichment of pediatric ARDS. Crit Care. 2026. PMID: 42387347. doi:10.1186/s13054-026-06174-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。